Vor Biopharma

Historical price data

Vor Biopharma is advancing telitacicept, a novel dual BAFF/APRIL inhibitor, to transform the treatment of autoimmune diseases by correcting underlying immune dysfunction. The asset is already approved and commercially successful in China for SLE, RA, and MG, providing significant de-risking and real-world validation. Vor's strategy leverages this foundation to pursue global registrations in high-need indications like Sjögren's Disease and gMG, targeting a multi-billion dollar market with a potentially best-in-class therapy.

A proprietary approach centered on telitacicept, a first-in-class TACI-Fc fusion protein that dually inhibits the BAFF and APRIL cytokines to modulate pathogenic B-cell activity and autoantibody production at the source.